(NASDAQ: MRNA) Moderna's forecast annual revenue growth rate of 4.56% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.11%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.31%.
Moderna's revenue in 2025 is $2,232,000,000.On average, 27 Wall Street analysts forecast MRNA's revenue for 2025 to be $756,746,214,744, with the lowest MRNA revenue forecast at $589,926,063,120, and the highest MRNA revenue forecast at $900,516,275,160. On average, 27 Wall Street analysts forecast MRNA's revenue for 2026 to be $835,272,796,656, with the lowest MRNA revenue forecast at $512,962,199,256, and the highest MRNA revenue forecast at $1,237,282,014,504.
In 2027, MRNA is forecast to generate $1,016,157,410,712 in revenue, with the lowest revenue forecast at $603,990,525,552 and the highest revenue forecast at $1,360,346,060,784.